Clinical Trial

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-11-21; most recent amendment 2026-02-12.
Status change: Not Yet Recruiting → Recruiting 2024-03-14
Trial Details
NCT Number NCT06151236
Lead Sponsor Melanoma Institute Australia
Collaborators: Bristol-Myers Squibb
Conditions Merkel Cell Carcinoma
Enrollment 20 participants
Start Date 2024-03-11
Primary Completion 2026-12 (estimated)
Study Completion 2034-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-17